Li Yangyang, Guo Yan, Chen Fengzhi, Cui Yuqing, Chen Xuesong, Shi Guangyue
Department of Breast Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province 150081, China.
Department of Breast Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province 150081, China; Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi Province 030013, China.
Transl Oncol. 2024 Jul;45:101980. doi: 10.1016/j.tranon.2024.101980. Epub 2024 May 2.
Male breast cancer (MBC) is a rare malignancy with a worse prognosis than female breast cancer (FBC). Current MBC treatment strategies are based on those for FBC. However, molecular differences between MBC and FBC with respect to prognosis and drug responses remain unclear.
After controlling for confounding factors with propensity score matching (PSM), differences between MBC and FBC were comprehensively analyzed using many types of data: survival, immune microenvironments, sex hormone responses, drug sensitivity, transcriptomes, genomes, epigenomes, and proteomes.
Overall survival (OS) and cancer-specific survival (CSS) were both worse for MBC than for FBC. Differentially expressed mRNAs were enriched in numerous cancer-related functions and pathways, with SPAG16 and STOX1 being as the most important prognosis-related mRNAs for MBC. Competing endogenous RNA (ceRNA) and transcription factor (TF)-mRNA regulatory networks contain potential prognostic genes. Nine genes had higher mutation frequencies in MBC than in FBC. MBC shows a comparatively poor response to immunotherapy, with five proteins that promote breast cancer progression being highly expressed in MBC. MBC may be more responsive than FBC to estrogen. We detected six United States Food and Drug Administration (FDA)-approved therapeutic target genes as being differentially expressed between MBC and FBC.
The poor prognosis of MBC compared to FBC is due to numerous molecular differences and resulting drug responses.
男性乳腺癌（MBC）是一种罕见的恶性肿瘤，其预后比女性乳腺癌（FBC）更差。目前MBC的治疗策略是基于FBC的治疗策略。然而，MBC和FBC在预后和药物反应方面的分子差异仍不清楚。
通过倾向评分匹配（PSM）控制混杂因素后，使用多种数据对MBC和FBC之间的差异进行综合分析：生存、免疫微环境、性激素反应、药物敏感性、转录组、基因组、表观基因组和蛋白质组。
MBC的总生存期（OS）和癌症特异性生存期（CSS）均比FBC差。差异表达的mRNA在众多癌症相关功能和途径中富集，SPAG16和STOX1是MBC最重要的预后相关mRNA。竞争性内源RNA（ceRNA）和转录因子（TF）-mRNA调控网络包含潜在的预后基因。9个基因在MBC中的突变频率高于FBC。MBC对免疫治疗的反应相对较差，有5种促进乳腺癌进展的蛋白在MBC中高表达。MBC可能比FBC对雌激素更敏感。我们检测到6个美国食品药品监督管理局（FDA）批准的治疗靶点基因在MBC和FBC之间存在差异表达。
与FBC相比，MBC预后较差是由于众多分子差异及由此导致的药物反应。
